Merck & Co., Inc. (MRK)’s MK-1084 Shows Promise in Early Cancer Trial

Merck & Co., Inc. (NYSE:MRK) has announced promising early results from its Phase 1 KANDLELIT-001 trial of MK-1084, an investigational KRAS G12C inhibitor, in patients with advanced colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations. The study found MK-1084 demonstrated a manageable safety profile and encouraging antitumor activity, both as a standalone treatment and in combination with other therapies, including KEYTRUDA and cetuximab.

Merck & Co., Inc. (MRK)’s MK-1084 Shows Antitumor Activity in Phase 1 Trial for KRAS G12C-Mutant Colorectal and Lung Cancer

Pixabay/Public Domain

In CRC, confirmed overall response rates (ORR) reached 38% with MK-1084 monotherapy, 46% with MK-1084 plus cetuximab, and 38% when combined with cetuximab and chemotherapy.

For NSCLC, ORRs were 38% for monotherapy, 77% with MK-1084 plus KEYTRUDA, and 53% with the addition of chemotherapy. Treatment-related adverse events were manageable across all study arms, with rates ranging from 58% in monotherapy to 97% in combination regimens.

These results, presented at the 2025 ASCO Annual Meeting, support further Phase 3 trials of MK-1084 in combination therapies for first-line treatment of KRAS G12C-mutant CRC and NSCLC. Merck & Co., Inc. (NYSE:MRK)’s senior leadership highlighted the findings as evidence of the company’s commitment to advancing innovative cancer treatments.

While we acknowledge the potential of MRK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRK and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.